Cell-mediated immune responses in tuberculosis

AM Cooper - Annual review of immunology, 2009 - annualreviews.org
Tuberculosis is primarily a disease of the lung, and dissemination of the disease depends
on productive infection of this critical organ. Upon aerosol infection with Mycobacterium …

Virulence factors of the Mycobacterium tuberculosis complex

MA Forrellad, LI Klepp, A Gioffré, J Sabio y Garcia… - Virulence, 2013 - Taylor & Francis
The Mycobacterium tuberculosis complex (MTBC) consists of closely related species that
cause tuberculosis in both humans and animals. This illness, still today, remains to be one of …

[HTML][HTML] Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

MD Tameris, M Hatherill, BS Landry, TJ Scriba… - The Lancet, 2013 - thelancet.com
Background BCG vaccination provides incomplete protection against tuberculosis in infants.
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …

Variable host–pathogen compatibility in Mycobacterium tuberculosis

S Gagneux, K DeRiemer, T Van… - Proceedings of the …, 2006 - National Acad Sciences
Mycobacterium tuberculosis remains a major cause of morbidity and mortality worldwide.
Studies have reported human pathogens to have geographically structured population …

The success and failure of BCG—implications for a novel tuberculosis vaccine

P Andersen, TM Doherty - Nature Reviews Microbiology, 2005 - nature.com
Over the past 50 years, the Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccine
against tuberculosis (TB) has maintained its position as the world's most widely used …

Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development

A Volz, G Sutter - Advances in virus research, 2017 - Elsevier
Abstract Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation
vaccine against smallpox and serves as a potent vector system for development of new …

Paediatric tuberculosis

SM Newton, AJ Brent, S Anderson… - The Lancet infectious …, 2008 - thelancet.com
Tuberculosis continues to cause an unacceptably high toll of disease and death among
children worldwide, particularly in the wake of the HIV epidemic. Increased international …

[HTML][HTML] Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans

M Jeyanathan, DK Fritz, S Afkhami, E Aguirre… - JCI insight, 2022 - ncbi.nlm.nih.gov
Background Adenovirus-vectored (Ad-vectored) vaccines are typically administered via im
injection to humans and are incapable of inducing respiratory mucosal immunity. However …

Vaccines against tuberculosis: where are we and where do we need to go?

THM Ottenhoff, SHE Kaufmann - PLoS pathogens, 2012 - journals.plos.org
In this review we discuss recent progress in the development, testing, and clinical evaluation
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …

Therapeutic vaccines for tuberculosis: an overview

R Bouzeyen, B Javid - Frontiers in Immunology, 2022 - frontiersin.org
Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world's deadliest bacterial
infection, resulting in more than 1.4 million deaths annually. The emergence of drug …